QT Vascular in potential sale of coronary products
Add BT as a preferred sourceMEDICAL technology firm QT Vascular is potentially selling its coronary products to a multinational firm.
In an announcement on Monday morning, it said that the term sheet both have entered into is non-legally binding and non-definitive, and it will continue to engage the buyer with the intention to complete the deal.
The Catalist-listed firm aims to continue generating value for shareholders from its mature products while further developing its drug-coated products and expanding its portfolio with new technologies, it added.
QT Vascular had also announced a potential transaction linked to certain coronary assets in October last year, which led to a surge in its share price.
Share with us your feedback on BT's products and services
TRENDING NOW
Digital Realty, STT GDC among data centre operators awarded 50 MW of new capacity in Singapore
Jardine C&C selling Singapore, Malaysia dealerships to Indonesia’s Chandra Asri for US$221 million gain
When every phone becomes a satellite phone, what happens to Asia’s telcos?
‘How come you’re so young?’: Gen Z couple takes on Singapore’s established bullion dealers
